

Today's date: \_\_\_\_\_

Intended date of injection: \_\_\_\_\_

## Prior Authorization Form – Yesintek®

**Buy-and-bill requests for this drug should be submitted through NaviNet®.**

### ONLY COMPLETED REQUESTS WILL BE REVIEWED.

Check one: ☐ New start ☐ Continued treatment

#### Patient information (please print)

Patient name	
Address	
City, state, ZIP	
Patient telephone #	
Patient ID	
Date of birth	Weight

#### Physician information (please print)

Prescribing physician	
Office address	
City, state, ZIP	
Office contact	
Office telephone #	
Fax #	NPI

**This drug will be delivered to the requesting physician for the formulation selected below:**

**Prefilled syringe:** \_\_\_\_\_ 45mg \_\_\_\_\_ 90mg or **Vial:** \_\_\_\_\_ 45mg \_\_\_\_\_ 130mg

**\*\* A copy of the prescription must accompany the medication request for delivery.\*\***

**1) Diagnosis for drug requested (must include ICD-10):** \_\_\_\_\_

#### 2) Patient medical information

##### *For Crohn's disease or ulcerative colitis only*

a. Does the patient have a documented history of failure, contraindication, or intolerance to at least one of the following? Check all that apply and list the drug(s) on the line provided below: ☐ Yes ☐ No

☐ Immunomodulators (e.g., azathioprine, 6-mercaptopurine, methotrexate); \_\_\_\_\_

☐ Corticosteroids (e.g., budesonide [Entocort® EC], prednisone, hydrocortisone, methylprednisolone); \_\_\_\_\_

☐ Biologic therapy (e.g., TNF blockers [including certolizumab {Cimzia®}, adalimumab {Humira®}, infliximab {Remicade®}, or vedolizumab (Entyvio®); \_\_\_\_\_

b. Had/Will the patient receive one intravenous infusion before switching to subcutaneous injections? ☐ Yes ☐ No

##### *For plaque psoriasis only*

a. Is the patient's chronic plaque psoriasis classified as moderate-to-severe? ☐ Yes ☐ No

b. Does the patient have a documented history of failure, contraindication, or intolerance to any of the following? ☐ Yes ☐ No  
Check all that apply and list the drug(s) on the line provided below:

☐ Topical steroids available by prescription only; \_\_\_\_\_

☐ Topical nonsteroids available by prescription only (e.g., topical calcipotriene [Dovonex®], topical anthralin, topical retinoids [Tazorac®]; \_\_\_\_\_

☐ Topical immunomodulators (e.g., pimecrolimus [Elidel®], tacrolimus [Protopic®]; \_\_\_\_\_

☐ Methotrexate; \_\_\_\_\_

☐ Oral retinoids (e.g., Soriatane®); \_\_\_\_\_

☐ Cyclosporine (e.g., Neoral, Gengraf); \_\_\_\_\_

##### *For psoriatic arthritis only*

a. Does the patient have a documented history of failure, contraindication, or intolerance to any disease-modifying antirheumatic drug (DMARD) such as, but not limited to, sulfasalazine, azathioprine, hydroxychloroquine, cyclosporine, methotrexate, or anti-tumor necrosis factor agents? ☐ Yes ☐ No

If yes, list drug(s): \_\_\_\_\_

#### 3) Prescription information

Quantity \_\_\_\_\_ refill x \_\_\_\_\_ month(s)

Instructions (include dose) \_\_\_\_\_ every \_\_\_\_\_ day(s)/ week(s)/ month(s)

Physician's signature \_\_\_\_\_

**Please fax this completed form to 215-761-9580.**